OR WAIT null SECS
Xellia Pharmaceuticals invests US$25 million in its Copenhagen, Denmark site to expand sterile manufacturing of products for treating antimicrobial resistant infections.
Xellia Pharmaceuticals held a ground-breaking ceremony for a new US$25-million expansion at its Copenhagen, Denmark site, the company announced in a Oct. 11, 2017 press release. The company has begun construction of a multi-story building that will house sterile manufacturing equipment and containment solutions in a purpose-built environment for manufacturing products for treating antimicrobial resistant infections.
This site also houses Xellia’s headquarters and is the company’s largest product manufacturing plant. It is responsible for manufacturing, stability testing, and packaging of both sterile APIs and finished dosage forms for anti-infectives such as vancomycin and colistimethate sodium. This upgrade in facilities will ensure that the company is able to continue to provide a reliable supply of injectable anti-infective critical care medicines.